Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions
Autism Spectrum Disorder
Interventions
DRUG

Propranolol

Propanolol will be given on a titration schedule in which participants will begin with small doses (single capsules) of the drug and increase to a larger dosage (divided over 3 capsules) over the course of three weeks. Participants aged 15-24 years will undergo an MRI.

DRUG

Placebo

Placebo will be given in the form preferred by the participant and on the same schedule as the propanolol regime. Participants aged 15-24 years will undergo an MRI.

DEVICE

Magnetic Resonance Imaging (MRI)

An MRI will be performed on participants aged 15-24 years.

Trial Locations (1)

65211

Thompson Center for Autism & Neurodevelopmental Disorders, Columbia

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

University of Missouri-Columbia

OTHER

NCT02871349 - Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response | Biotech Hunter | Biotech Hunter